报价延迟最少15分钟:2026/06/12 10:14 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
30.625 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.77/--
|
|
企业价值
3.64B
|
| 资产负债 |
|
每股账面净值
-4.80
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helicalpeptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between -catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types. |
